First patients treated with Ovation iX Abdominal Stent Graft system in Europe

16 September 2015 (Last Updated September 16th, 2015 18:30)

US-based TriVascular Technologies has treated the first European patients with the Ovation iX Abdominal Stent Graft system in Germany and England.

US-based TriVascular Technologies has treated the first European patients with the Ovation iX Abdominal Stent Graft system in Germany and England.

Based on the Ovation platform, the Ovation iX system provides physicians with options for greater procedural consistency and ease of use.

The company noted with the new system, contralateral gate access can be achieved either by retrograde cannulation or through a new, built-in crossover lumen.

"The iX system is the latest delivery system improvement from TriVascular in what is now a five year experience with the Ovation platform in Germany."

The patent pending crossover lumen technology provides physicians an optional capability designed for easier and more predictable cannulation of the contralateral limb when they need it.

Earlier this year, the Ovation iX system received CE Mark and approval from US Food and Drug Administration (FDA).

In Europe, the first implants were carried out at Herz- und Gefäßzentrum Bad Bevensen, Germany and Watford General Hospital in the UK.

Herz- und Gefäßzentrum Bad Bevensen Vascular Surgery head Dr Thomas Nolte said: "The Ovation platform, based on its breadth of application and the strength of its clinical data, is my frontline device.

"The new Ovation iX delivery system allows me to deploy the Ovation stent graft with increased ease and predictability.

"The iX system is the latest delivery system improvement from TriVascular in what is now a five year experience with the Ovation platform in Germany."

Since 2010, more than 1,000 patients, including the first cases completed in Europe, have been treated with the Ovation platform in Germany.

The company noted the Ovation iX Abdominal Stent Graft system shows its ongoing commitment to providing physicians with clinically valuable technologies.